secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0000950170-25-067452
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics Q1 net income $3.7M, revenue $22.1M; reaffirms FY2025 guidance $118–128M
--------------------------------------------------------------------------------

- Net income $3.7M ($0.03 basic EPS) vs $9.9M in Q1 2024; revenue $22.1M, down 19% due to ETUARY decline from prior year one-time campaign.
- FY2025 revenue guidance reiterated at $118–128M (2024: $105.8M); commercial launches of nintedanib (May 2025) and avatrombopag (March 2025) expected to drive H2 growth.
- Phase 3 Hydronidone trial for CHB liver fibrosis completed data lock; topline results expected Q2 2025. IND approved for pirfenidone for radiation-induced lung injury.
- Non-GAAP adjusted net income $2.9M vs $8.2M; cash $51.3M as of March 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000095017025067452/0000950170-25-067452-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000095017025067452/gyre-20250509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-067452

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer